Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pegsunercept · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pegsunercept (PEG sTNF-RI) | DRUG | - |
Inclusion Criteria: - Subjects who have completed 24 weeks of double-blind treatment in a previous protocol (20000201 or 20000198) - Females of childbearing potential and males must practice adequate contraception, in the judgement of the investigator, during the course of the study - The subject or...
Top 20 of 28 competitors
Pegsunercept is an investigational small molecule being studied for the treatment of Rheumatoid Arthritis. It is currently in Phase 2 clinical development. The drug has been evaluated in a completed Phase 2 trial that assessed the safety of extended treatment with Pegsunercept in subjects with Rheumatoid Arthritis.
Pegsunercept is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The company is conducting clinical research on this investigational drug for the treatment of Rheumatoid Arthritis.
Pegsunercept is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, which evaluated the safety of extended treatment with Pegsunercept in patients with Rheumatoid Arthritis.
Pegsunercept has one completed clinical trial registered under NCT00111423. This Phase 2 study, titled 'Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA)', enrolled 216 participants and was completed. The trial was randomized and double-blind.
Yes, Pegsunercept is also known as PEG sTNF-RI. The clinical trial NCT00111423 refers to the drug as Pegsunercept (PEG sTNF-RI), indicating that these names are used interchangeably for the same investigational drug being developed for Rheumatoid Arthritis.